Sign Out
Teratogenicity of rifampicin in humans has not been reported. However, rifampicin is reported to cross the placental barrier although effect of the substance on the human fetus is not known.
Before starting the treatment with Natricin, inform the doctor if the patient is pregnant or expecting pregnancy. If possible, Natricin Forte should not be taken in the first 3 months of pregnancy.
The reliability of oral contraceptives may be affected by rifampicin. Alternative contraceptive measures may be considered.
Continue with Google